Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial Read more about Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Read more about A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers.
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial Read more about CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Read more about Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors. Read more about First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.
Characterization of GM-CSF and G-CSF expressing cell subtypes in the tumor microenvironment using the Paletrra™ multiplex immunofluorescence assay integrated with RNAscope™ Read more about Characterization of GM-CSF and G-CSF expressing cell subtypes in the tumor microenvironment using the Paletrra™ multiplex immunofluorescence assay integrated with RNAscope™
A multiomics approach using transcriptomic and spatial analysis to identify predictive immune biomarkers of response and toxicity following chemotherapy in head & neck cancers Read more about A multiomics approach using transcriptomic and spatial analysis to identify predictive immune biomarkers of response and toxicity following chemotherapy in head & neck cancers
Deep phenotyping and spatial interrogation of the NSCLC tumor microenvironment using the fully validated Next Generation MultiOmyx™ Platform Read more about Deep phenotyping and spatial interrogation of the NSCLC tumor microenvironment using the fully validated Next Generation MultiOmyx™ Platform